Physician profile

Michael K Distler

Physical Medicine & Rehabilitation · Grand Rapids, MI

NPI 1215193917

$654.61

in general payments reported to CMS, 2019-2025

1 company · $147 in 2025

The $147 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$610.72

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $654.61 2022-2025 Proclaim, Absolute Pro

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael K Distler

$654.61

in general payments reported 2019-2025

Years
2022-2025
Top company
Abbott Laboratories
Context
The $147 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).

https://glasscript.com/doctor/145341/michael-k-distler

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.